17 February 2023 - The recommendation is based on clinical data for Moderna's bivalent Omicron targeting COVID-19 vaccine, mRNA.1273.214.
Moderna today announced that Health Canada has authorised the use of its Omicron targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron) in children and adolescents 6 to 17 years of age.